CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma.

CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget. 2018 Jul 03;9(51):29743-29752 Authors: Givechian KB, Garner C, Garban H, Rabizadeh S, Soon-Shiong P Abstract Somatic mutations in DNA repair genes have been clinically associated with chemosensitivity, although few studies have interrogated the nucleotide synthesis pathways that supply DNA repair processes. Previous work suggests that bladder urothelial carcinoma is uniquely enriched for mutations in nucleotide excision repair genes, and that these mutations are associated with response to platinum-based therapy and favorable survival. Conversely, the de novo pyrimidine synthesis pathway has recently emerged as a putative clinical target. This anabolic process is thought to supply DNA repair processes such as nucleotide excision repair; that is, DNA repair enzymes may require a sufficient nucleotide supply available to reverse the intended genotoxic damage of systemic chemotherapy in rapidly proliferating cancer cells. Therefore, we explored the prognostic complementarity between de novo pyrimidine synthesis and nucleotide excision repair expression in a total of 570 bladder urothelial carcinoma patients. Ultimately, we show that the de novo pyrimidine synthesis gene CAD is associated with poor survival (P = 0.008) and is co-altered with the nucleotide excision repair gene POLD2. High expression of POLD2 was also associated w...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

Conditions:   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation;   Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltr ating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Urothelial Carcinoma;   MTAP Negative Interventions:   Drug: Avelumab;   Drug: Pemetrexed Sponsors:   M.D. Anderson Cancer Center;   National Cancer&nbs...
Source: - Category: Research Source Type: clinical trials
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Open radical cystectomy (ORC) with pelvic lymph node dissection is the standard of care treatment for very high-risk non –muscle-invasive and muscle-invasive urothelial carcinoma of the bladder (UCB), providing durable local cancer control [1–3]. Even when performed by experienced surgeons, it is associated with significant morbidity including bleeding, pain associated with the incision and prolonged abdominal wal l retraction, as well as major fluid shifts [4]. Additionally, visibility of the surgical field can be difficult in the deep pelvic and retrovesical spaces [5–9].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Non-muscle-invasive bladder cancer (NMIBC) includes stage Ta and stage T1 tumors and carcinoma in situ (CIS). Grading of Ta tumors subdivides these lesions into papillary urothelial neoplasms of low malignant potential and low- and high-grade noninvasive papillary urothelial carcinoma. CIS is by definition high-grade and the majority of stage T1 tumors are of high-grade. This pathologic heterogeneity is associated with divergent clinical outcome, with significantly worse prognosis for patients with T1 tumors or CIS.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Seminars article Source Type: research
To determine the association of micropapillary urothelial carcinoma (MUC) variant histology with bladder cancer outcomes after radical cystectomy.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
AbstractBladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer tre...
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
This study assessed a national healthcare intervention launched in Sweden in 2015 to reduce the time between macroscopic haematuria, diagnosis and treatment of urinary tract cancer. METHODS: The outcome of the first 11 months was evaluated in 1697 individuals referred to a standardized care pathway for urinary tract cancer compared with 174 patients with conventionally diagnosed urothelial carcinoma. RESULTS: Among the referred individuals, 317 (19%) were diagnosed with cancer, 1034 (61%) had a benign diagnosis and 345 (20%) had a negative evaluation. Bladder cancer was the most common malignant diagnosis [262/317 ...
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Authors: Kato T, Nakayama R, Haba T, Kawaguchi M, Komiya A, Koike H Abstract Segmental ureterectomy (SU) represents a promising alternative for the treatment of upper tract urothelial carcinomas (UTUCs) as it is a less invasive procedure and guarantees the preservation of renal units. The present study evaluated oncological outcomes and renal functions following SU when compared with radical nephroureterectomy (RNU). A total of 26 patients with UTUCs who underwent SU (n=12) or RNU (n=14) were retrospectively evaluated. SU was performed in patients with clinically unifocal disease. In the SU group, the following sur...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion,NEDD8 possessed important roles in regulating the progression of BC cells and was associated with the poor prognosis of patients, which may become a potential therapeutic target of BC.This article is protected by copyright. All rights reserved.
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Bladder cancer is the fifth most common cancer in the United States and one of the costliest cancers to treat. Compared to other cancer types, bladder cancer has been understudied, and there is a need for informative mouse bladder cancer models that resemble the clinical situation and allow for evaluation of chemotherapeutic or immunotherapeutic agents. The orthotopic murine bladder cancer model MB49 resembles non-muscle invasive, nonmetastatic urothelial carcinomas and provides an opportunity to study the anti-tumor effects of immune cell checkpoint inhibitors. Moreover, successful tumor cell implantation of MB49 cells fa...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Gastroschisis Repair | Genetics | Study